STOCK TITAN

Tenax Therapeutics: ADAR1 reports 16.4% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Tenax Therapeutics, Inc. (TENX) is the issuer in an amended beneficial-ownership report by ADAR1 Capital Management, LLC and Daniel Schneeberger, which lists 7,447,000 common shares, or 16.4%, as beneficially owned as of October 31, 2026.

The shares are held directly by private investment funds managed by ADAR1 and its separately managed accounts. ADAR1 and Schneeberger report shared voting and dispositive power; Schneeberger is ADAR1’s sole manager and may be deemed to indirectly beneficially own the shares. ADAR1 reported 6,524,151 shares, or 14.3%, as of September 30, 2026. The reported amounts exclude shares underlying pre-funded warrants exercisable for 59,073 shares, each subject to a 4.99% beneficial ownership limitation.

Beneficially owned common shares 7,447,000 shares Reported by ADAR1 Capital Management and Daniel Schneeberger as of October 31, 2026
Percentage of class 16.4% Reported as of October 31, 2026
Beneficially owned common shares 6,524,151 shares ADAR1’s reported holdings as of September 30, 2026
Percentage of class 14.3% ADAR1’s reported ownership as of September 30, 2026
Shares underlying pre-funded warrants 59,073 shares Excluded from the reported beneficial ownership amounts
Beneficial ownership limitation 4.99% Limit applicable to each pre-funded warrant
beneficially owned regulatory
"7,447,000 shares of common stock ... may be deemed to be indirectly beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
pre-funded warrants financial
"hold pre-funded warrants exercisable for 59,073 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
beneficial ownership limitation regulatory
"each such pre-funded warrant is subject to a 4.99% beneficial ownership limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
shared voting power regulatory
"Shared Voting Power 7,447,000.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 7,447,000.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TENX shares did ADAR1 Capital Management and Daniel Schneeberger report owning?

ADAR1 Capital Management and Daniel Schneeberger reported beneficial ownership of 7,447,000 common shares, or 16.4%, as of October 31, 2026. The shares are held directly by private investment funds managed by ADAR1 and its separately managed accounts; the report describes Schneeberger as ADAR1’s sole manager.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





88032L605

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 7,447,000 shares of common stock, $0.0001 par value per share ("Common Stock"), of Tenax Therapeutics, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1") and separately managed accounts of ADAR1 as of October 31, 2026. Such securities may be deemed to be indirectly beneficially owned by ADAR1. In addition to the shares reported above, certain private investment funds managed by ADAR1 and separately managed accounts of ADAR1 hold pre-funded warrants exercisable for 59,073 shares of Common Stock. The shares of Common Stock issuable upon exercise of these pre-funded warrants are excluded from the amounts reported in boxes 6, 8, 9 and 11 because each such pre-funded warrant is subject to a 4.99% beneficial ownership limitation. The percentage in box 11 is based on 45,536,448 shares of Common Stock outstanding as of October 31, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 5, 2026. As of September 30, 2026, ADAR1 held 6,524,151 shares of Common Stock of the Issuer owned directly by private investment funds managed by ADAR1 and separately managed accounts of ADAR1. ADAR1 beneficially owned 14.3% of the Common Stock of the Issuer based on 45,536,448 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 5, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 7,447,000 shares of common stock, $0.0001 par value per share ("Common Stock"), of Tenax Therapeutics, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1") and separately managed accounts of ADAR1 as of October 31, 2026. Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1. In addition to the shares reported above, certain private investment funds managed by ADAR1 and separately managed accounts of ADAR1 hold pre-funded warrants exercisable for 59,073 shares of Common Stock. The shares of Common Stock issuable upon exercise of these pre-funded warrants are excluded from the amounts reported in boxes 6, 8, 9 and 11 because each such pre-funded warrant is subject to a 4.99% beneficial ownership limitation. The percentage in box 11 is based on 45,536,448 shares of Common Stock outstanding as of October 31, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 5, 2026. As of September 30, 2026, ADAR1 held 6,524,151 shares of Common Stock of the Issuer owned directly by private investment funds managed by ADAR1 and separately managed accounts of ADAR1. ADAR1 beneficially owned 14.3% of the Common Stock of the Issuer based on 45,536,448 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 5, 2026.


SCHEDULE 13G



ADAR1 Capital Management, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/16/2026
Daniel Schneeberger
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:11/16/2026

Keep reading